Phylex Biosciences Set To Develop AI-Derived mRNA Nanoparticle Vaccine Against Metapneumovirus
New Vaccine to Combat Growing Threat in California
DEL MAR, California – March 12, 2026 – Phylex Biosciences, a vaccine developer based in Southern California, announces the first comprehensive research project to develop an AI-derived mRNA nanoparticle vaccine against the human metapneumovirus, which has recently been spreading throughout Northern California.
The Phylex mRNA nanoparticle vaccine technology has already demonstrated success against two major viruses, SARS-CoV-2 in collaboration with the Pasteur Institute and the Nipah virus in collaboration with the US Centers for Disease Control. Phylex mRNA vaccines encode for a nanoparticle that displays 60 copies of an optimized antigen of the virus. According to Phylex, that same technology can be readily applied to the company’s vaccine in development for the human metapneumovirus.
The human metapneumovirus, or hMPV, is a respiratory virus that is currently circulating in areas of Northern California where high concentrations of hMPV have been detected in wastewater. hMPV has similar symptoms to influenza and, like influenza, is seasonal and transmitted by close contact. The infection can progress to severe disease, particularly in young children and older adults.
Crucially the implementation of Phylex vaccine technology is uniquely accelerated by the latest AI deep learning tools applied to the design of antigens. The AI-derived optimized antigen is displayed on a nanoparticle that mimics the virus to elicit a strong and long-lasting immune response.
“Our research program intends to respond quickly to this expanding health threat” said Pascal Brandys, co-founder and CEO of Phylex Biosciences. “Our technology of mRNA vaccine encoding for highly immunogenic nanoparticles is directly applicable to the human metapneumovirus.”
“All our vaccines benefit from the combined advantages of AI-derived accelerated design, mRNA technology for speed of manufacturing and development, and the efficacy of a nanoparticle”, Brandys continued. “Our human metapneumovirus vaccine initiative will uniquely benefit from AI-accelerated research to deliver a rapid response to the expanding threat of this virus”.
About Phylex BioSciences
Founded at the beginning of the COVID-19 pandemic by genomics pioneer Pascal Brandys and virologist Jens Herold, Phylex BioSciences is the first company to pursue the development of AI-derived mRNA nanoparticle vaccines against pathogenic viruses.
Contact Media Relations:
+1-858-350-9100
media@phylexbio.com